

## SUPPLEMENTARY DATA

**Table S1. Percentage of patients receiving edoxaban 60 and 30 mg doses according to local labels**

	<b>Edoxaban Total (N=26,823)</b>		<b>Edoxaban 60 mg (n=14,348)</b>		<b>Edoxaban 30 mg (n=12,475)</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Body weight ≤60 kg						
Europe	1310	10.3	488	5.1	822	27.2
South Korea/Taiwan	846	34.0	202	16.9	644	50.0
Japan	6000	55.2	168	5.6	5832	74.2
Global	8156	31.3	858	6.2	7298	60.0
Creatinine clearance 15–50 mL/min						
Europe	2391	21.0	708	8.3	1683	59.8
South Korea/Taiwan	704	29.7	133	11.8	571	46.2
Japan	3439	31.9	69	2.3	3370	43.3
Global	6534	26.7	910	7.2	5624	47.5